Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

BLEOMYCIN FOR INJECTION USP DIN 02367351

Status: Cancelled Pre Market
Holder: SANDOZ CANADA INCORPORATED
Molecule: BLEOMYCIN (BLEOMYCIN SULFATE)

Health Canada record

Active ingredient(s)BLEOMYCIN (BLEOMYCIN SULFATE) 15 UNIT
Dosage formPowder For Solution
RouteIntravenous; Intrapleural; Intramuscular; Subcutaneous
SchedulePRESCRIPTION
ClassHuman
ATCL01DC01 BLEOMYCIN
Original market date
Current status date01-Aug-2019
SourceHealth Canada DPD

Establishment licence of the holder

Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing BLEOMYCIN (BLEOMYCIN SULFATE)

DINProductCompanyFormStrengthStatus
02265982BLEOMYCIN FOR INJECTIONFRESENIUS KABI CANADA LTDPowder For SolutionBLEOMYCIN (BLEOMYCIN SULFATE) 15 UNITMarketed
02566346BLEOMYCIN FOR INJECTIONMARCAN PHARMACEUTICALS INCPowder For SolutionBLEOMYCIN (BLEOMYCIN SULFATE) 15 UNITApproved
02131692BLEOMYCIN FOR INJECTION USPPFIZER CANADA ULCPowder For SolutionBLEOMYCIN (BLEOMYCIN SULFATE) 15 UNITMarketed

Notices of Compliance

NOCDateSubmissionReason
122932011-04-27Abbreviated New Drug Submission (ANDS)
Request a quote for BLEOMYCIN FOR INJECTION USP

How to read a Canadian DIN record